Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
In the prescription pharmaceuticals business, Asacol, Dificlir and Veltassa performed strongly. In the consumer healthcare business, products including the Hepalyse range struggled due to unfavorable weather and the impact of competing products, while the royal jelly range and overseas chondroitin bulk business grew.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥45,461 million (YoY +13.8%) |
| Operating profit | ¥5,646 million (YoY +55.1%) |
| Ordinary income | ¥5,191 million (YoY +95.4%) |
| Profit attributable to owners of the parent | ¥3,959 million (YoY +127.8%) |
| Net income per share | ¥89.82 |
| Equity ratio | End of the current fiscal period 62.1 / End of previous period 60.3 |
| Total assets | ¥178,816 million |
| Net assets | ¥111,314 million |
| Cash flows from operating activities | ¥5,642,176 thousand |
| Cash flows from investing activities | ¥-1,389,490 thousand |
| Cash flows from financing activities | ¥-3,166,016 thousand |
| Cash and cash equivalents at end of period | ¥29,034,745 thousand |
| Full-year earnings forecast | Net Sales ¥95,000 million (YoY +6.6%) / Operating profit ¥13,000 million (YoY +5.1%) / Ordinary income ¥13,000 million (YoY +17.7%) / Net income ¥10,000 million (YoY +18.3%) |
| Annual Dividend Forecast | 49 yen → 51 yen |
| Segment revenue | Prescription Pharmaceutical Business ¥31,538,301 thousand (YoY +20.3%), Consumer Healthcare ¥13,848,865 thousand (YoY +1.3%), Other ¥74,117 thousand (YoY -3.6%) |
| Segment profit | Prescription Pharmaceutical Business ¥5,883,986 thousand, Consumer Healthcare ¥2,968,420 thousand, Other ¥99,535 thousand |
| Depreciation and amortization | ¥4,249,750 thousand |
| Impairment loss | No applicable matters |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Loss on disposal of non-current assets ¥0 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate Yes / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name Not applicable |
| Material subsequent events | Tillotts Pharma AG entered into an equity transfer agreement with Aenova Holding GmbH on 23 October 2026 to acquire all equity interests in Haupt Pharma Wülfling GmbH. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for securities analysts, institutional investors and the media) |
| Issued Shares at Period-End | 50,119,190 |
| Treasury Shares at Period-End | 6,039,802 |
| Factors Behind Changes in Business Performance | In the prescription pharmaceuticals business, Asacol, Dificlir and Veltassa performed strongly. In the consumer healthcare business, products including the Hepalyse range struggled due to unfavorable weather and the impact of competing products, while the royal jelly range and overseas chondroitin bulk business grew. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Strong performance by the overseas core products Asacol, Dificlir and the domestic product Veltassa drove the prescription pharmaceuticals business. In the consumer healthcare business, products including the Hepalyse range struggled due to unfavorable weather and the impact of competing products, while the royal jelly range and overseas chondroitin bulk business grew.